RAC Strategic Planning & Communication 3 — Questions and Answers
Question 1: A regulatory affairs professional is preparing a briefing document for a Type B FDA meeting. Which element is MOST critical to include to make the meeting productive?
- A full copy of the investigational brochure
- Specific questions formatted to elicit yes/no agency commitments (Correct answer)
- A list of all previous FDA correspondence
- A summary of competitor products on the market
Correct answer: Specific questions formatted to elicit yes/no agency commitments
FDA expects specific, clearly worded questions in briefing documents so the agency can provide focused, actionable responses during the meeting.
Question 2: Which ICH guideline provides a framework for assessing genotoxic impurities in pharmaceutical products, directly influencing regulatory submission strategy?
- ICH Q3A
- ICH M7 (Correct answer)
- ICH E6
- ICH S2
Correct answer: ICH M7
ICH M7 provides guidance on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals, setting acceptable intake thresholds.
Question 3: A company must decide whether to pursue Breakthrough Therapy designation for a new oncology drug. Which criterion is MOST relevant to this designation?
- The drug targets an unmet need in a rare pediatric disease only
- Preliminary clinical evidence shows substantial improvement over existing therapies for a serious condition (Correct answer)
- The drug has been approved in at least one foreign market
- The manufacturing process uses a novel continuous manufacturing platform
Correct answer: Preliminary clinical evidence shows substantial improvement over existing therapies for a serious condition
Breakthrough Therapy designation requires preliminary clinical evidence showing substantial improvement over available therapies on a clinically significant endpoint for a serious condition.
Question 4: In strategic regulatory planning, what does 'benefit-risk communication' primarily involve?
- Communicating product pricing justification to payers
- Transparently conveying the balance between a product's therapeutic benefits and its known risks to regulators and patients (Correct answer)
- Describing manufacturing risk mitigation strategies to inspectors
- Reporting financial risks associated with regulatory delays to investors
Correct answer: Transparently conveying the balance between a product's therapeutic benefits and its known risks to regulators and patients
Benefit-risk communication involves clearly presenting and contextualizing both the therapeutic benefits and the safety risks of a product to regulators, prescribers, and patients.
Question 5: A company submitting an NDA receives a Complete Response Letter (CRL) from FDA. What is the MOST appropriate immediate strategic response?
- File a citizen petition challenging the CRL
- Conduct a thorough analysis of the CRL deficiencies and request a Type A meeting to discuss the path forward (Correct answer)
- Resubmit the NDA immediately without changes
- Abandon the submission and pursue a different indication
Correct answer: Conduct a thorough analysis of the CRL deficiencies and request a Type A meeting to discuss the path forward
Analyzing the CRL deficiencies thoroughly and requesting a Type A meeting allows the sponsor to clarify FDA's concerns and develop a targeted remediation plan.
Question 6: Which of the following BEST describes the purpose of a regulatory gap analysis?
- Identifying differences between a product's label and its promotional materials
- Comparing current data packages against agency requirements to identify missing or insufficient evidence (Correct answer)
- Auditing internal SOPs against GMP regulations
- Reviewing patent expirations relative to product lifecycle plans
Correct answer: Comparing current data packages against agency requirements to identify missing or insufficient evidence
A regulatory gap analysis systematically compares the existing data package against regulatory requirements to identify deficiencies that must be addressed before submission.
Question 7: Under the EU MDR (Regulation 2017/745), which body is responsible for reviewing and certifying medical devices before they can be CE marked?
- The European Medicines Agency (EMA)
- A designated Notified Body (Correct answer)
- The national competent authority of the manufacturer's country
- The European Commission directly
Correct answer: A designated Notified Body
Under EU MDR, Notified Bodies are accredited third-party organizations designated to perform conformity assessments and issue CE certificates for medical devices.
RAC Strategic Planning & Communication 3
A regulatory affairs professional is preparing a briefing document for a Type B FDA meeting.
Which element is MOST critical to include to make the meeting productive?